FTRE Fortrea Holdings Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1965040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.4%
TTM net income YoY93.2%
TTM EPS YoY94.1%
Revenue 3-yr CAGR-2.7%
Net income 3-yr CAGR—
Margins
Gross margin20.0%
Operating margin0.5%
Net margin-2.6%
FCF margin6.3%
EBITDA margin3.4%
Returns
ROE-12.3%
ROA-2.5%
ROIC (approx.)0.7%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets80.6%
Debt / equity1.98x
Current ratio0.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.94x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.72B | $2.70B | $2.84B | $2.84B | $3.06B |
| Cost of revenue | $2.22B | $2.16B | $2.25B | $2.11B | $2.45B |
| Gross profit | $503.80M | $534.20M | $590.60M | $724.40M | $604.40M |
| SG&A expense | $456.40M | $560.70M | $448.10M | $416.10M | $303.10M |
| Operating income | -$872.60M | -$161.90M | $32.00M | $187.10M | $114.30M |
| Interest expense | — | — | $100,000 | $200,000 | $200,000 |
| Pretax income | -$983.00M | -$275.00M | -$30.50M | $187.00M | $136.40M |
| Income tax | $3.20M | -$3.50M | $1.20M | $41.10M | $38.40M |
| Net income | -$986.20M | -$328.50M | -$25.20M | $186.20M | $98.00M |
| EBITDA | -$794.60M | -$75.00M | $130.00M | $280.70M | $280.60M |
| EPS (basic) | -10.81 | -3.67 | -0.29 | 2.09 | 1.10 |
| EPS (diluted) | -10.81 | -3.67 | -0.29 | 2.09 | 1.10 |
| Weighted avg. shares (diluted) | — | 89.50M | 88.80M | 88.80M | 88.80M |
| Banking | |||||
| Net interest income | — | — | -$69.70M | -$200,000 | — |
| Balance sheet | |||||
| Cash & equivalents | $174.60M | $118.50M | $108.60M | $110.40M | $94.60M |
| Current assets | $897.20M | $948.20M | $1.25B | $1.25B | — |
| PP&E, net | — | — | — | $164.90M | — |
| Goodwill | $960.00M | $1.71B | $1.74B | $1.71B | $2.08B |
| Intangibles | $622.00M | $655.70M | $728.10M | $823.30M | — |
| Total assets | $2.72B | $3.58B | $4.33B | $4.29B | — |
| Current liabilities | $913.30M | $949.50M | $778.40M | $699.00M | — |
| Short-term debt | $4.80M | $74.80M | $26.10M | $0 | — |
| Long-term debt | $1.05B | $1.05B | $1.57B | $0 | — |
| Total debt | $1.05B | $1.12B | $1.59B | $0 | — |
| Total liabilities | $2.15B | $2.22B | $2.62B | $945.30M | — |
| Shareholders' equity | $563.50M | $1.36B | $1.71B | $3.34B | $3.26B |
| Net debt | $878.20M | $1.01B | $1.48B | -$110.40M | — |
| Shares outstanding | 93.10M | 89.70M | 88.80M | 0 | — |
| Cash flow statement | |||||
| Operating cash flow | $113.50M | $262.80M | $168.40M | $82.70M | $169.80M |
| Capital expenditure | $25.20M | $25.50M | $40.30M | $54.40M | $26.50M |
| Free cash flow | $88.30M | $237.30M | $128.10M | $28.30M | $143.30M |
| Investing cash flow | $14.40M | $251.60M | -$31.80M | -$54.00M | -$26.20M |
| Financing cash flow | -$76.30M | -$497.80M | -$140.80M | -$6.30M | -$128.50M |
| Depreciation & amortization | $78.00M | $86.90M | $98.00M | $93.60M | $166.30M |
| Stock-based compensation | $74.40M | $58.40M | $42.70M | $25.40M | $27.50M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.